News FocusGenomics

After the Gold Rush: Gene Firms Reinvent Themselves

See allHide authors and affiliations

Science  20 Sep 2002:
Vol. 297, Issue 5589, pp. 1982-1984
DOI: 10.1126/science.297.5589.1982

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Private investment in genomics boomed in 2000-01; now there's a glut of sequence data and many firms are struggling to deliver drugs. One strategy genomics companies are adopting is to home in on proteins that are important in disease processes to come up with targets for new drugs. Another tactic is to de-emphasize basic genetics and shift resources into focused therapeutics. Yet another--for firms than can afford it--is to buy a company that already has plans to make drugs.